HHS’ Plan B Interference Could Rattle Industry

By Dan Schiff / Email the Author / “The Tan Sheet” Dec. 12, 2011, Vol. 19, No. 50
Rx-to-OTC Switch / Word Count: 264 / Article # 05111212017

Purchase this Article

$35.00 Buy Now

For $35.00, purchase this 264-word article and receive immediate online access. 100% Satisfaction Guarantee.

View a complete sample article »

Already a Subscriber?

Log in for complete access.

Questions?

Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.

+ Show All | – Hide All

There are no current related articles

Offers & Events

Topics Covered in this Article

Click a keyword for related articles.
General Topics
biotech
Rx to OTC switch
FDA
OTC labeling
Subjects
Regulatory
Product Approvals
Drugs
Industries
Consumer Products
Otc Drugs
Biopharmaceuticals
Branded Prescription
Generics
Small Molecule Generics
Therapeutic Area(s) of Focus
Gynecology
Contraceptive
Sexual Health
Female
Regions
North America
United States
Companies
Teva Pharmaceutical Industries Ltd.

Log In

Email Address

Password

Remember Me

Forgot your password?

Don’t Have an Account?

If your employer has a site license, create your account to begin using it. Simply click ‘Create An Account’ button below to register now.

Otherwise, please explore our free content subscriptions.

Create an account

Enter the email address associated with your account and a temporary password will be sent to you.

Email Address

Need help? Contact us at (800) 332-2181, +1 (908) 547-2159, or custcare@elsevier.com

Email Article

* Required field

* To:

For multiple recipients, separate email addresses with a semi-colon.

* Your Name:

* Your Email:

Subject: HHS’ Plan B Interference Could Rattle Industry

* Add a personalized message to your email:

Please Note: Only individuals with subscriptions to “The Tan Sheet” will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.

or Cancel